Péron J - Search Results

1

Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer.

Péron J, Roy P, Ding K, Parulekar WR, Roche L, Buyse M. Péron J, et al. Br J Cancer. 2015 Mar 17;112(6):971-6. doi: 10.1038/bjc.2015.55. Br J Cancer. 2015. PMID: 25688740 Free PMC article. Clinical Trial.

2

Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.

Péron J, Ceruse P, Lavergne E, Buiret G, Pham BN, Chabaud S, Favier B, Girodet D, Zrounba P, Ramade A, Fayette J. Péron J, et al. Anticancer Drugs. 2012 Oct;23(9):996-1001. doi: 10.1097/CAD.0b013e32835507e5. Anticancer Drugs. 2012. PMID: 22643048

3

Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.

Péron J, Poupart M, Ceruse P, Ramade A, Girodet D, Zrounba P, Fayette J. Péron J, et al. Anticancer Drugs. 2012 Nov;23(10):1107-11. doi: 10.1097/CAD.0b013e328358d226. Anticancer Drugs. 2012. PMID: 22954504

4

The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.

Péron J, Roy P, Ozenne B, Roche L, Buyse M. Péron J, et al. JAMA Oncol. 2016 Jul 1;2(7):901-5. doi: 10.1001/jamaoncol.2015.6359. JAMA Oncol. 2016. PMID: 27124210

5

An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring.

Péron J, Buyse M, Ozenne B, Roche L, Roy P. Péron J, et al. Stat Methods Med Res. 2018 Apr;27(4):1230-1239. doi: 10.1177/0962280216658320. Epub 2016 Aug 2. Stat Methods Med Res. 2018. PMID: 27487842

6

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.

Péron J, Roy P, Conroy T, Desseigne F, Ychou M, Gourgou-Bourgade S, Stanbury T, Roche L, Ozenne B, Buyse M. Péron J, et al. Oncotarget. 2016 Dec 13;7(50):82953-82960. doi: 10.18632/oncotarget.12761. Oncotarget. 2016. PMID: 27765912 Free PMC article. Clinical Trial.

7

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

Saad ED, Zalcberg JR, Péron J, Coart E, Burzykowski T, Buyse M. Saad ED, et al. Among authors: peron j. J Natl Cancer Inst. 2018 Mar 1;110(3):232-240. doi: 10.1093/jnci/djx179. J Natl Cancer Inst. 2018. PMID: 29933439 Review.

8

The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma.

Péron J, Giai J, Maucort-Boulch D, Buyse M. Péron J, et al. Pancreas. 2019 Feb;48(2):275-280. doi: 10.1097/MPA.0000000000001234. Pancreas. 2019. PMID: 30629024 Clinical Trial.

9

Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit.

Péron J, Lambert A, Munier S, Ozenne B, Giai J, Roy P, Dalle S, Machingura A, Maucort-Boulch D, Buyse M. Péron J, et al. J Natl Cancer Inst. 2019 Nov 1;111(11):1186-1191. doi: 10.1093/jnci/djz030. J Natl Cancer Inst. 2019. PMID: 30838402 Free PMC article.

10

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.

Colomban O, Tod M, Leary A, Ray-Coquard I, Lortholary A, Hardy-Bessard AC, Pfisterer J, Du Bois A, Kurzeder C, Burges A, Péron J, Freyer G, You B. Colomban O, et al. Among authors: peron j. Clin Cancer Res. 2019 Sep 1;25(17):5342-5350. doi: 10.1158/1078-0432.CCR-18-3335. Epub 2019 Apr 1. Clin Cancer Res. 2019. PMID: 30936122

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

604 results

Search Page

Filters